Appendix 3B
December 10, 2019
Imagion Biosystems has released Appendix 3B: New issue announcement, application for quotation of additional securities and agreement. Read Appendix 3B.
Category: Investor updates
Change In Director’s Interest Notice
December 9, 2019
Imagion Biosystems has released Change of Director’s Interest Notices for David Ludvigson, Mark Van Asten, and Robert Proulx. Read the Change in Director’s Interest Notices:
Form 604: Notice of change of interests of substantial holder
December 2, 2019
Imagion Biosystems Limited has released “Form 604: Notice of change of interests of substantial holder” to the market. Read Form 604.
Form 605: Notice of ceasing to be a substantial holder
November 29, 2019
Imagion Biosystems Limited has announced “Form 605: Notice of ceasing to be a substantial holder.” Read Form 605.
Imagion Biosystems receives $300K order for supply of nanoparticles
November 27, 2019
Imagion Biosystems Limited announced the NewPhase Ltd., an Israeli biotechnology company developing cancer treatments, has placed an order totaling approximately $300k for the supply of
Completion of Renounceable Rights Issue
November 22, 2019
Imagion Biosystems has announced the successful completion of the renounceable rights issue raising approximately $3.6 million. Read Imagion Biosystems’ Right Issue raises $3.6 million.
Imagion Biosystems' Patent Issued in India
November 13, 2019
Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, has been issued patent #320872 from the Government
Offer Update and Appendix 3B
November 8, 2019
Imagion Biosystems Limited (ASX: IBX) (the Company) refers to its renounceable pro rata right issue offer of new fully paid ordinary shares (New Shares) announced
Supplementary Prospectus
November 8, 2019
Imagion Biosystems Limited has announced a supplementary prospectus (Supplementary Prospectus) which shall be read with the prospectus dated 28 October 2019 (Prospectus) and issued by
Rights Commence Trading
October 31, 2019
Imagion Biosystems Limited (ASX: IBX) (the Company), is pleased to confirm that the rights associated with the Company’s Renounceable Rights Issue announced on 28 October